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Abstract: Minimal-invasive hepatectomy (MIH) has been increasingly performed for benign and
malignant liver lesions with most promising short-term results. However, the oncological role of
MIH in the treatment of patients with colorectal liver metastases (CRLM) needs further investigation.
Clinicopathological data of patients who underwent liver resection for CRLM between 2012 and 2017 at
the Department of Surgery, Charité-Universitätsmedizin Berlin, and the Inselspital Bern were assessed.
Postoperative outcomes und long-term survivals of patients following MIH were compared with those
after conventional open hepatectomy (OH) after 1:1 propensity score matching. During the study period,
229 and 91 patients underwent liver resection for CRLM at the Charité Berlin and the Inselspital Bern,
respectively. Patients who underwent MIH in one of the two centers (n = 69) were compared with a
matched cohort of patients who underwent OH. MIH was associated with lower complication rates (23%
vs. 44%, p = 0.011), shorter length of intensive care unit stay (ICU, 1 vs. 2 days, p = 0.043), shorter length
of hospital stay (7 vs. 11 days, p < 0.0001), and a reduced need for intraoperative transfusions (12% vs.
25%, p = 0.047) compared to OH. R0 status was achieved in 93% and 75% of patients after MIH and OH,
respectively (p = 0.005). After a median follow-up of 31 months, MIH resulted in similar five-year overall
survival (OS) rate (56% vs. 48%, p = 0.116) in comparison to OH. MIH for CRLM is associated with
lower postoperative morbidity, shorter length of ICU and hospital stay, reduced need for transfusions,
and comparable oncologic outcomes compared to the established OH. Our findings suggest that MIH
should be considered as the preferred method for the treatment of curatively resectable CRLM.
Keywords: colorectal liver metastases; laparoscopic liver surgery; minimal invasive surgery
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1. Introduction
The most common site of metastatic tumor spread in patients with colorectal cancer is the liver.
At time of diagnosis, 20% of patients present with synchronous colorectal liver metastases (CRLM) [1],
and up to 25% of patients are at risk to develop metachronous CRLM over time [2]. Liver resection
remains the mainstay of a multimodal curative therapeutic approach for CRLM, enabling long-term
survivals. In the last decades, advances in the multimodal treatment of patients with CRLM have
achieved five-year overall survival rates of up to 58% after hepatectomy [3,4].
Since the introduction of laparoscopic liver surgery in the early 1990s [5,6], minimal-invasive
hepatectomy (MIH) has been widely adopted for benign and malignant lesions of the liver,
including hepatocellular carcinoma [7,8] and CRLM [9]. Doubts about laparoscopic liver resection
concerning the general complexity of the technique and cost-effectiveness are gradually declining,
since benefits in short-term outcomes have been reported in several retrospective studies and were
confirmed in meta-analyses [10,11]. MIH for CRLM has been associated with less intraoperative blood
loss, lower need for transfusion, lower postoperative morbidity rates, and shorter length of hospital
stay in comparison to open hepatectomy (OH) [10,12,13]. Reports on oncologic results have already
demonstrated the non-inferiority of MIH in terms of the rate of patients with tumor-free resection
margins (R0 resection), overall survival (OS), and disease-free survival (DFS) [9,14]. These findings
have indicated that MIH is a valid alternative to OH in the most recent Southampton guidelines for
laparoscopic liver surgery [15].
Scientific evidence on the feasibility of MIH for CRLM is mostly based on retrospectively collected
data. To date, only one randomized controlled study (RCT) from Norway has been conducted showing
benefits for minimal-invasive CRLM resection concerning postoperative morbidity and length of
hospital stay [13]. However, this study was single-center and included only patients with minor
resections, thus may not be widely applicable for patients with extended disease.
Although long known [16], propensity-score matching (PSM) analysis gained popularity in recent
years as a statistical method to adjust for known confounding factors and thus reduce the impact of
selection bias in retrospective studies [17]. PSM has been often used for the comparison of surgical
techniques in an effort to create comparable treatment groups [10]. Using propensity-score based
analysis, previous European multi-center studies have given insight into the short- and long-term
outcomes of MIH in comparison to OH for CRLM [18,19]. In this study, we aimed to share the current
experience of two major hepatobiliary centers that regularly perform MIH.
The objective of this study was to evaluate the postoperative and oncologic outcomes of patients
undergoing MIH for CRLM compared to those of patients undergoing OH in a bi-centric setting using
PSM analysis. In addition, the inter-center comparison of postoperative and long-term outcomes
between two major hepatobiliary centers in Berlin, Germany, and Bern, Switzerland, intended to
provide further insight into each center’s approach to the treatment of patients with CRLM.
2. Experimental Section
2.1. Patient Inclusion Criteria
Approval for this study was obtained from the Ethics Commission of Charité-Universitätsmedizin
Berlin (EA2/006/16) and the Ethics Commission of the Canton of Bern (2018-01576). Clinicopathological
data on 229 and 91 consecutive patients who underwent resection for CRLM from 2012 to
2017, at the Department of Surgery, Campus Charité Mitte and Campus Virchow Klinikum,
Charité-Universitätsmedizin Berlin, and the Department of Visceral Surgery and Medicine, lnselspital,
Bern University Hospital, University of Bern, respectively, were collected.
Inclusion criterion was a curative intended resection, defined as the ability to remove all
radiologically evident disease. Patients were excluded from the analysis if they were <18 years
old, if extended hemihepatectomies were performed, and if microwave ablations or other surgical
procedures (e.g., resection of the primary tumor) were concomitantly performed with hepatectomy.
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2.2. Preoperative Assessment
Patients with CRLM presenting in each department routinely underwent a standardized
preoperative evaluation protocol that included medical history, physical examination, serum laboratory
tests, and an anesthesia evaluation. Tumor staging and the estimation of the future liver remnant
(FLR) volume was determined via cross-sectional imaging (triphasic contrast-enhanced computed
tomography or magnetic resonance imaging with liver-specific contrast agents) as needed.
An institutional multidisciplinary tumor board in each center consisting of surgeons, hepatologists,
oncologists, and specialized radiologists discussed each case and recommended the best individual
treatment strategy for each patient.
2.3. Surgical Procedure
Surgical procedures were performed as previously described [20–23]. At the beginning of every
procedure, following laparotomy or laparoscopy, the peritoneal cavity was examined to rule out any
previously undiagnosed tumor spread. Intraoperative ultrasound of the liver was used to validate
the exact location and extent of CRLM as determined by imaging studies. Conventional OH was
initiated with a modified Makuuchi incision [24]. For MIH in both centers, patients were kept in
a supine position with legs spread apart (French position) [25]. MIH was performed either via
multiport laparoscopic surgery (MLS, transumbilical 12 mm optical trocar and further 5 mm and
12 mm trocars), single-incision laparoscopic surgery (SILS; GelPort®, Applied Medical, Rancho Santa
Margarita, CA, USA, via 4–5 cm midline incision for three trocars, additional 5 mm port in upper
left abdominal quadrant, if needed), or hand-assisted laparoscopic surgery (HALS; handport via
5 cm supraumbilical incision and 2–3 additional 12 mm ports). Specimen were retrieved via a
Pfannenstiel incision, extension of the umbilical incision or by using an existing scar. Total or selective
hepatic vascular exclusion was utilized for major parenchymal transections, as needed. For MIH in
both centers, liver parenchyma dissection was performed using a combination of following devices
and instruments: energy devices (Thunderbeat®, Olympus K.K., Tokyo, Japan, or Harmonic Ace®,
Ethicon Inc., Somerville, NJ, USA), laparoscopic cavitron ultrasonic surgical aspirator (CUSA®,
Valleylab Boulder, CO, USA), Waterjet (ERBEJET®, ERBE Tübingen, Germany), and vascular stapler
(Echelon™, Ethicon, Somerville, NJ, USA) or Endo GIA™ (Medtronic, Dublin, Ireland).
The resection of≥ 3 contiguous liver segments defined major hepatectomy according to Couinaud’s
classification [26]. Location of CRLM was stratified by technical difficulty in segments II, III, IVb, V,
and VI, and segments I, IVa, VII, and VIII. The latter was defined as technical more difficult.
2.4. Postoperative Management
After surgery, patients were occasionally admitted to a surgical intensive care unit (ICU) if
needed, where they were monitored for postoperative complications such as intra-abdominal bleeding,
infection, biliary fistula, wound infection, pneumonia, pleural effusions, and liver failure. After routine
removal of the nasogastric tube on the same day, oral intake and mobilization was anticipated on
postoperative day 1. Intra-abdominal drains were either not used at all or removed as soon as the
discharge was unremarkable. Blood tests were postoperatively regularly performed to assess liver
function and cholestasis and rule out the development of an infectious collection. Any complication
or death within 90 days after surgery defined postoperative morbidity and mortality, respectively.
Postoperative complications were graded according to the classification of Clavien and Dindo and
major complications were defined as ≥3a [27]. After surgery, all cases were re-evaluated in our
multidisciplinary tumor board and postoperative treatment was recommended according to current
guidelines [28].
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2.5. Histological Evaluation
Resected specimens were evaluated by a pathologist to confirm the diagnosis of CRLM and to
determine the resection margin status (R). R0 was defined as a surgical margin of ≥1 mm free of
malignant cells [29].
2.6. Statistical Analysis
Propensity score analysis was used to match patients who underwent MIH for CRLM with a cohort
of patients who were treated with OH in each center separately. A 1:1 PSM was performed using a logistic
regression model with a match tolerance of 0.1 based on the following matching parameters: patient age,
sex, ASA (American Society of Anesthesiologists) status, comorbidities (diabetes, hypertension,
coronary heart disease, pulmonary disease, and/or renal disease), presence of solitary or multiple
CRLM, sequence of hepatic tumor spread (synchronous or metachronous), preoperative chemotherapy,
and resection extent (including major or minor hepatectomy). Matched cohorts from both centers were
then merged for a pooled comparison of MIH with OH.
Quantitative and qualitative variables were expressed as medians (range) and frequencies.
The chi-square or Fisher’s exact test for categorical variables, and the Wilcoxon signed-rank test for
continuous variables, were used as appropriate to compare between groups. Patient characteristics
and postoperative outcomes were compared between the matched MIH and OH cohorts as well as
between the MIH patients in Berlin and Bern.
Using the Kaplan-Meier method, overall survival (OS) was calculated from the date of resection
to the date of death or last follow-up and disease-free survival (DFS) was calculated from the date of
resection to the date of first recurrence or last follow-up. Comparisons between survival rates were
performed using log-rank tests.
p values < 0.05 were considered statistically significant. Statistical analyses were performed using
the SPSS software package, version 25 (IBM, Armonk, NY, USA).
3. Results
3.1. Patient Characteristics
During the study period, 229 and 91 consecutive patients underwent hepatectomy for CRLM at the
Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité Berlin, and the
Department of Visceral Surgery und Medicine, lnselspital, Bern, respectively, and were included in this
study. OH was performed in 251 patients (78%) (n = 185 in Berlin, n = 66 in Bern) and 69 patients (22%)
were treated with MIH (n = 44 in Berlin, n = 25 in Bern).
Patient cohorts in Berlin differed significantly before matching (MIH vs. OH) regarding the
rate of patients presenting with CRLM > 50 mm including 35% and 16% in the OH and MIH group,
respectively (p = 0.016). Additionally, the extent of liver resection was significantly different between
the two groups (p < 0.0001), since there were more open major hepatectomies during the study period.
Before matching MIH with OH in Bern, there were significant differences between the two groups
regarding the proportion of patients presenting with single CRLM (76% vs. 42%, p = 0.003) and CRLM
> 50 mm (12% vs. 36%, p = 0.023). In addition, the N stage of the primary tumor was more advanced
in the OH group (p = 0.048). Significantly less major hepatectomies (4% vs. 33%, p = 0.004) and less
anatomic resections (4% vs. 55%, p < 0.0001) were performed in the MIH cohort compared to the
OH group.
After PSM, pooled analysis of MIH (n = 69 patients) versus OH (n = 69 patients) is summarized in
Table 1. Both groups (MIH vs. OH) were comparable regarding sex (male: 68% vs. 55%, p = 0.115),
median age (65 vs. 63 years, p = 0.210), median BMI (25 vs. 25 kg/m2, p = 0.718), ASA physical status
(p = 0.470), and location of the primary tumor (colon and rectum: 54% vs. 61% and 46% vs. 39%, p = 0.390).
Moreover, no significant differences regarding the sequence of liver tumor spread (synchronous: 46%
vs. 45%, p = 0.864), and the proportion of patients presenting with CRLM > 50 mm (15% vs. 27%,
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p = 0.074) or solitary CRLM (51% vs. 44%, p = 0.439) were found. However, CRLM were more
frequently located in segments I, IVa, VII, and VIII in the OH group (p = 0.005). The rate of patients
treated with preoperative chemotherapy was comparable between both groups (60% vs. 62%, p = 0.727).
Anatomic resections were performed in 39% and 51% in the MIH and OH group, respectively (p = 0.171).
Both groups had equal amounts of major resections (33% vs. 33%, p = 1), and the extent of hepatectomy
was comparable (p = 0.660) between the two groups. The median duration of surgery was similar
between the groups (218 vs. 250 min, p = 0.078). Positive resections margins were found in 7% and
25% after MIH and OH, respectively (p = 0.005). A comparable number of patients were monitored on
the ICU postoperatively (83% vs. 88%, p = 0.370). The length of ICU stay (1 vs. 2 days, p = 0.043) and
length of hospital stay (7 vs. 11 days, p < 0.0001) were significantly shorter after MIH than after OH.
The need for blood transfusions was reduced after MIH (12% vs. 25%, p = 0.047).
Table 1. Characteristics of propensity-score matched patients who underwent hepatectomy for CRLM
in Berlin and Bern (n = 138).
Variable OH(n = 69)
MIH
(n = 69) p
Gender, n (%) 0.115
Female 31 (45) 22 (32)
Male 38 (55) 47 (68)
Age, years, median (range) 63 (30–86) 65 (27–89) 0.210
Age > 65 years, n (%) 32 (46) 35 (51) 0.609
BMI, kg/m2, median (range) 25 (18–46) 25 (18–40) 0.718
BMI > 30 kg/m2, n (%) 11 (16) 14 (21) 0.480
ASA physical status, n (%) 0.470
1 2 (3) 0 (0)
2 34 (49) 32 (46)
3 32 (47) 35 (51)
4 1 (1) 2 (3)
Comorbidities, n (%)
Diabetes 10 (15) 12 (17) 0.642
Hypertension 29 (42) 29 (42) 1
Coronary heart disease 4 (6) 7 (10) 0.346
Pulmonary disease 4 (6) 4 (6) 1
Renal disease 4 (6) 6 (9) 0.511
Localization of primary, n (%) 0.390
Colon 42 (61) 37 (54)
Rectum 27 (39) 32 (46)
Synchronous CRLM, n (%) 31 (45) 32 (46) 0.864
Size of biggest CRLM > 50 mm, n
(%) 18 (27) 10 (15) 0.074
Solitary CRLM, n (%) 30 (44) 35 (51) 0.439
CRLM in segments II, III, IVb, V,
and VI, n (%) 56 (81) 63 (91) 0.084
CRLM in segments I, IVa, VII, and
VIII, n (%) 52 (75) 36 (52) 0.005
Preoperative chemotherapy, n (%) 43 (62) 41 (60) 0.727
T stage of primary, n (%) 0.360
1 4 (6) 3 (5)
2 4 (6) 8 (13)
3 43 (64) 41 (67)
4 16 (24) 9 (15)
N stage of primary, n (%) 0.038
0 23 (34) 33 (54)
1 33 (49) 16 (26)
2 11 (16) 11 (18)
3 0 (0) 1 (2)
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Table 1. Cont.
Variable OH(n = 69)
MIH
(n = 69) p
UICC stage of primary, n (%) 0.031
1 5 (7) 7 (11)
2 7 (10) 14 (21)
3 23 (34) 9 (14)
4 33 (49) 36 (54)
Tumor grading of primary, n (%) 0.443
G1 2 (4) 0 (0)
G2 47 (82) 38 (84)
G3 8 (14) 7 (16)
Postoperative ICU stay, n (%) 59 (88) 57 (83) 0.370
Length of ICU stay, days, median
(range) 2 (0–37) 1 (0–23) 0.043
Length of hospital stay, days,
median (range) 11 (4–109) 7 (2–59) <0.0001
90-day complications, n (%) 30 (44) 16 (23) 0.011
90-day major complications, n (%) 17 (25) 12 (17) 0.296
90-day mortality, n (%) 2 (3) 1 (1) 0.559
Anatomic resection, n (%) 35 (51) 27 (39) 0.171
Major resection, n (%) 23 (33) 23 (33) 1
Positive resection margins, n (%) 17 (25) 5 (7) 0.005
Resection margin width in R0
resected patients, mm, median
(range)
2 (1–20) 3 (1–40) 0.430
Surgical technique, n (%) 0.660
right hepatectomy 13 (19) 12 (17)
right hepatectomy and wedge
resections or segmental resections 6 (9) 8 (12)
left hepatectomy 4 (6) 1 (1)
left hepatectomy and wedge
resections or segmental resections 0 (0) 2 (3)
left lateral hepatectomy 4 (6) 4 (6)
segmentectomy/wedge resection 30 (43) 30 (43)
bisegmentectomy 12 (17) 12 (17)
Need for transfusion, n (%) 17 (25) 8 (12) 0.047
Duration of operation, minutes,
median (range) 250 (106–513) 218 (46–602) 0.078
Postoperative chemotherapy, n
(%) 22 (32) 22 (32) 1
CRLM, colorectal liver metastases; OH, open hepatectomy; MIH, minimal-invasive hepatectomy; BMI, body mass
index; ASA, American Society of Anesthesiologists; UICC, Union internationale contre le cancer;
ICU, intensive care unit.
3.2. Postoperative Morbidity and Mortality
Postoperative morbidity was significantly lower after MIH than after OH (23% vs. 44%, p = 0.011).
Postoperative mortality was not significantly different between the two techniques (1% vs. 3%,
p = 0.559).
3.3. Overall Survival and Disease-Free Survival
After a median follow-up time of 31 months, the 5-year OS rates were 56% and 48% after MIH
and OH, respectively (p = 0.116; Figure 1). Five-year DFS rates were 46% and 27% after MIH and OH,
respectively (p = 0.018).
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Figure 1. Overall survival of propensity-score matched patients who underwent hepatectomy for
CRLM in Berlin and Bern (n = 138). MIH, minimal-invasive hepatectomy; OS, overall survival; OH,
open hepatectomy; CRLM, colorectal liver metastases
3.4. Comparison of Clinicopathological Characteristics and Outcomes of Patients Who Underwent MIH in
Berlin vs. Bern
Characteristics of patients who underwent MIH in Berlin (n = 44) were compared with those of
patients in B n (n = 25) (Table 2). Patient-related parameters were comparable between the two centers.
No significant differences were found concerning age (p = 0.453), BMI (p = 0.513), ASA status (p = 0.163),
or presence of comorbidities. The rate of patients with CRLM > 5 mm (16% vs. 12%, p = 0.657) and
synchronous CRLM (43% vs. 52%, p = 0.480) was equivalent between the two centers. CRLM were
equally located in segments II, III, IVb, V, and VI (p = 0.180), and segments I, IVa, VII, and VIII of
the liver (p = 0.306). However, patients presented with solitary CRLM more frequently in Bern than
i Berlin (76% vs. 36%, p = 0.002). More major (50% vs. 4%, p < 0.0001) and anatomic resections
(59% vs. 4%, p < 0.0001) were performed in Berlin than in Bern. In general, the extent of MIH was
different between Berlin and Bern (p = 0.002). Whereas a large p rt of minimal-invasive res ctions in
Berlin were hemihepatectomies, the majority of laparoscopic tr ated patients in Bern underwent wedge
resections or s gmentectomies, thus also resulting in s gnificant differen es regarding the median
duration of the ope ation (290 vs. 125 min, p < 0.0001), postoperative morbidity rates (32% vs. 8%,
p = 0.024), and l ngth of hospital stay (9 vs. 5 days, p < 0.0001). There were m re patients in intens ve
care in Berlin than in Bern (91% vs. 68%, p = 0.022); howe er, length of ICU stay was comparable
between the centers (1 vs. 2 days, p = 0.283). Postoperative mortality after MIH was comparable in
both centers (p = 1). Additionally, there were no significant differences regarding positive resection
margins (p = 0.151), and the need for transfusions (p = 1).
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Table 2. Comparison of characteristics and outcomes between patients who underwent
minimal-invasive hepatectomy for CRLM in Berlin or Bern (n = 69).
Variable Berlin(n = 44)
Bern
(n = 25) p
Gender, n (%) 0.110
Female 17 (39) 5 (20)
Male 27 (61) 20 (80)
Age, years, median (range) 65 (27–89) 66 (29–84) 0.453
Age > 65 years, n (%) 21 (48) 14 (56) 0.509
BMI, kg/m2, median (range) 25 (18–40) 26 (19–34) 0.513
BMI > 30 kg/m2, n (%) 8 (19) 6 (24) 0.630
ASA physical status, n (%) 0.163
1 0 (0) 0 (0)
2 21 (48) 11 (44)
3 23 (52) 12 (48)
4 0 (0) 2 (8)
Comorbidities, n (%)
Diabetes 8 (18) 4 (16) 1
Hypertension 19 (43) 10 (40) 0.797
Coronary heart disease 3 (7) 4 (16) 0.225
Pulmonary disease 1 (2) 3 (12) 0.132
Renal disease 4 (9) 2 (8) 1
Localization of primary, n (%) 0.423
Colon 22 (50) 15 (60)
Rectum 22 (50) 10 (40)
Synchronous CRLM, n (%) 19 (43) 13 (52) 0.480
Size of biggest CRLM > 50 mm, n (%) 7 (16) 3 (12) 0.657
Solitary CRLM, n (%) 16 (36) 19 (76) 0.002
CRLM in segments II, III, IVb, V, and VI, n (%) 42 (96) 21 (84) 0.180
CRLM in segments I, IVa, VII, and VIII, n (%) 25 (57) 11 (44) 0.306
Preoperative chemotherapy, n (%) 23 (52) 18 (72) 0.109
T stage of primary, n (%) 0.086
1 1 (2) 2 (8)
2 8 (22) 0 (0)
3 23 (62) 18 (75)
4 5 (14) 4 (17)
N stage of primary, n (%) 0.437
0 18 (49) 15 (63)
1 12 (32) 4 (17)
2 6 (16) 5 (21)
3 1 (3) 0 (0)
UICC stage of primary, n (%) 0.919
1 5 (12) 2 (8)
2 8 (20) 6 (24)
3 6 (15) 3 (12)
4 22 (54) 14 (56)
Tumor grading of primary, n (%) 0.412
G1 0 (0) 0 (0)
G2 24 (89) 14 (78)
G3 3 (11) 4 (22)
Postoperative ICU stay, n (%) 40 (91) 17 (68) 0.022
Length of ICU stay, days, median (range) 1 (0–23) 2 (0–3) 0.283
Length of hospital stay, days, median (range) 9 (3–59) 5 (2–10) <0.0001
90-day complications, n (%) 14 (32) 2 (8) 0.024
90-day major complications, n (%) 11 (25) 1 (4) 0.027
90-day mortality, n (%) 1 (2) 0 (0) 1
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Table 2. Cont.
Variable Berlin(n = 44)
Bern
(n = 25) p
Anatomic resection, n (%) 26 (59) 1 (4) <0.0001
Major resection, n (%) 22 (50) 1 (4) <0.0001
Positive resection margins, n (%) 5 (11) 0 (0) 0.151
Resection margin width in R0 resected patients,
mm, median (range) 4 (1–40) 3 (1–20) 0.519
Surgical technique, n (%) 0.002
right hepatectomy 11 (25) 1 (4)
right hepatectomy and wedge resections or
segmental resections 8 (18) 0 (0)
left hepatectomy 1 (2) 0 (0)
left hepatectomy and wedge resections or
segmental resections 2 (4) 0 (0)
left lateral hepatectomy 4 (9) 0 (0)
wedge resection 13 (30) 17 (68)
bisegmentectomy 5 (11) 7 (28)
Need for transfusion, n (%) 5 (11) 3 (12) 1
Duration of operation, minutes, median (range) 290 (121–602) 125 (46–235) <0.0001
Postoperative chemotherapy, n (%) 13 (30) 9 (36) 0.580
CRLM, colorectal liver metastases; BMI, body mass index; ASA, American Society of Anesthesiologists; UICC,
Union internationale contre le cancer; ICU, intensive care unit.
Five-year OS rates (Berlin vs. Bern: 52% vs. 59%, p = 0.091; Figure 2) and DFS rates (Berlin vs.
Bern: 47% vs. 44%, p = 0.577) were statistically equivalent between the two centers.
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Figure 2. Overall survival of patients who underwent minimal-invasive hepatectomy for CRLM in
Berlin or Bern (n = 69). OS, overall survival; CRLM, colorectal liver metastases
Forty-three percent (n = 3/7) and 67% (n = 2/3) of patients who deceased following MIH in the
observed time period in Berlin and Bern, respectively (p = 1), died due to cancer progression including
intrahepatic recurrence. Two of the three patients suffering cancer-related death in Berlin had initially
underwent major MIH because of extended liver tumor burden, and none of these three patients
were selected for repeat hepatectomy due to extended recurrent disease burden or insufficient FLR.
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Instead of re-resection, one patient underwent local brachytherapy, one patient was administered
palliative chemotherapy, and the third was lost to follow-up. In Bern, both patients, who died of
cancer progression following laparoscopic hepatectomy underwent initially minor liver resections
(bisegmentectomy and wedge resection) and were able to undergo repeat MIH for limited intrahepatic
recurrence. After diagnosis of intrahepatic recurrence, patients lived for another 6, 9, and 10 months in
Berlin, and for another 27 and 28 months in Bern, respectively.
4. Discussion
Our study on a bicentric experience from the Charité Berlin (Campus Charité Mitte and Campus
Virchow-Klinikum) and the Inselspital Bern compared the postoperative and oncologic outcomes of
patients who underwent MIH for CRLM with those of propensity-score matched patients treated
with OH. In comparison to conventional OH, our results indicated lower postoperative complication
rates, shorter length of ICU and hospital stay, and lower rates of intraoperative blood transfusions for
patients undergoing MIH. MIH was associated with oncologic outcomes equivalent to those after OH.
The advantages of MIH over OH for CRLM have been previously reported in the literature.
Recent studies found benefits regarding postoperative morbidity, length of hospital stay, blood loss,
and the need for transfusions with equivalent oncologic outcomes in comparison to OH [10,12,14,30–32].
These findings have been mainly derived from retrospective data since RCTs are often faced with
methodical and patient-recruitment related challenges [33]. So far, only one RCT has been completed
evaluating MIH for CRLM [13] while another had to be cancelled early due to a slow accrual process [34].
For this reason, PSM analysis has been introduced aiming to overcome treatment bias in retrospective
studies by assembling patient cohorts with minimal differences in clinicopathological features allowing
for a meaningful comparison [35,36]. To date, consensus regarding the optimal parameters that should
be included in PSM is lacking. Since our objective was to eliminate all patient- and tumor-related
factors that could influence outcomes after surgery, we decided to include all variables concerning
the general condition of the patient, the tumor characteristics, the administration of preoperative
chemotherapy, and the extent of hepatectomy. Various studies performed PSM to compare the outcomes
of laparoscopic versus open resection for CRLM, most recently coming from Italy [12], and the USA [14].
Earlier studies were analyzed in a meta-analysis which is entirely based on propensity-score matched
data [10].
Within the framework of our PSM analysis, we report on a comparably high rate of major MIH
for CRLM with 50% in Berlin and 33% in the entire cohort, respectively [12]. Of note, Fretland et al.
defined parenchymal-sparing liver resections in the design of their RCT with the switch to major
hepatectomy if needed [13]. To our knowledge, only few groups performed >50% major hepatectomies
in the laparoscopic group [31,37]. Due to the influence of the extent of hepatectomy on postoperative
outcomes, these findings need to be acknowledged when comparing the results of our study with
others. However, our study confirmed the findings of previous studies, which have shown that MIH is
associated with lower morbidity after surgery compared to OH [13,14,32]. Postoperative morbidity
(23% vs. 44%, p = 0.011) was significantly reduced after MIH, whereas major postoperative morbidity
was comparable between MIH and OH (17% vs. 25%, p = 0.296).
Moreover, our results showed at least equivalent oncologic outcomes between MIH and OH (5-year
OS: 56% vs. 48%, p = 0.116; 5-year DFS: 46% vs. 27%, p = 0.018). Previous studies reported comparable
survivals after open and laparoscopic hepatectomy for CRLM [12]. Patient- and tumor-related
factors that may have an influence on survival after surgery are comorbidities, size, and number
of CRLM, rate of preoperative chemotherapy, and extent of hepatectomy. These parameters were
comparable between the groups after PSM, supporting our opinion that MIH may provide oncologically
sufficient outcomes.
Furthermore, oncologic outcomes are generally known to be influenced by the presence of
malignant cells in the surgical margins (R1) allowing for early tumor recurrence [29]. Notably,
positive resection margins were significantly decreased after MIH in comparison to OH in this study
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(7% vs. 25%, p = 0.005). However, median resection margin width in R0 resected patients was
comparable between OH and MIH, as previously shown [38]. Margin width following MIH was also
comparable between the two centers. The implementation of standardized and routinely performed
intraoperative ultrasound both in MIH and OH has allowed for higher rates of R0 resections in the
recent years. However, the possibility that the surgeon might evaluate and determine the resection
margins more conservatively when performing MIH [9], especially due to the different tactile feedback
and during the learning curve could explain the improved R0 resection rate after MIH. Additionally,
despite thorough PSM taking into consideration numerous cancer-related characteristics we could
probably not entirely eliminate bias in the selection of the matched OH cases resulting in the inclusion
of some more advanced disease. Furthermore, CRLM were more frequently located in segments I,
IVa, VII, and VIII of the liver in the OH group compared to the MIH group. Hepatectomy on these
segments are known to be more difficult to perform [39], and this may have translated into a higher R1
rate in this group, and may have negatively influenced the oncologic outcome among OH patients [40].
In addition, more extensive tumor burden requiring OH may also be reflective of unfavorable tumor
biology, which, in turn, may be responsible for higher R1 resection rates [41–43].
Currently, perioperative chemotherapy has been widely adapted as an integral component in
the multimodal treatment of patients with CRLM [44]. The establishment of modern chemotherapy
regimens was one reason to exclude patients treated before 2012. Guidelines recommend the use of
preoperative systemic therapy to downsize the hepatic tumor burden and consequently convert patients
with unresectable disease to a resectable state [45,46]. Additionally, patients with initially resectable
CRLM may profit from preoperatively administered chemotherapy by reducing the presence of
malignant cells in the resection margins resulting in prolonged progression-free survival [44]. Our data
suggest that patients in both cohorts (MIH and OH) may have benefited equally from the positive effects
of chemotherapy as it was administered to equivalent percentages of patients preoperatively. However,
possible side effects of neoadjuvant cytotoxic agents (e.g., steatosis, steatohepatitis, or sinusoidal
changes) need to be taken into consideration, impairing the function and regenerative capacity of the
otherwise healthy remaining liver tissue [47].
Finally, in an effort to elucidate the improved OS for patients after MIH, postoperative morbidity
following liver resection for CRLM may have played a role as it has been proven to affect OS
and DFS negatively [48–52]. It is hypothesized that postoperative morbidity prolongs a phase of
immunosuppression allowing residual tumor cells to proliferate and to induce local recurrence [53].
We found a significantly reduced incidence of overall complications after MIH in comparison to OH in
our study, suggesting a positive impact on long-term survival after MIH. Moreover, postoperative
complications may have delayed the onset of adjuvant chemotherapy as part of the multimodal
treatment concept further contributing to diminished overall survival, as seen in patients after
colorectal cancer surgery [54].
Another interesting finding of our study was that MIH correlated with a shorter length of ICU
and hospital stay compared to OH. Laparoscopic techniques are considered to diminish the stress that
surgical procedures exert on the human body, and thus help to preserve and eventually restore organ
function after surgery in an accelerated timeline. Benefits of MIH include earlier postoperative oral
intake, optimized postoperative pain control, and earlier mobilization after surgery. In addition to
the reduced morbidity, these factors may have also contributed to an earlier discharge for patients
after MIH.
In this study, we compared the results of patients, who underwent MIH, in the Charité Berlin
und the Inselspital Bern. Both groups were equivalent regarding patient-related characteristics but
differed significantly in tumor-specific features. In Bern, MIH was mostly selected for patients with
solitary CRLM, and segmental resections were predominantly performed. This resulted in reduced
morbidity (8% vs. 32%, p = 0.024) and shorter length of hospital stay after MIH in comparison to Berlin
(5 vs. 9 days, p < 0.0001) without diminishing R0 resection rates. In contrast, more patients in Berlin
presented with higher tumor burden making more extensive hepatic resections necessary. These major
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MIHs for multiple CRLM were then followed by higher complication rates and longer length of hospital
stay in comparison to Bern. However, the results from both centers showed comparable low mortality
rates, and prolonged long-term survivals.
When deciding for a liver resection strategy, surgeons are confronted with two conflicting
objectives; on the one side, extensive hepatic disease requires an adequate resection extent in order
to achieve R0 resection and prevent tumor recurrence. On the other side, as much non-tumorous
liver tissue as possible needs to be preserved aiming to avoid postoperative liver insufficiency. This is
further aggravated by the aforementioned risks of preoperatively administered chemotherapy on
the histopathological and functional integrity of the residual liver parenchyma. An initially major
hepatectomy may impede the selection of patients for repeat liver resection in case of intrahepatic
recurrence. Additionally, extended tumor burden requiring hemihepatectomy or more is a surrogate
factor for advanced disease with a higher risk for earlier and disseminated recurrence. In our study,
patients who died of intrahepatic recurrence following MIH in Berlin, presented with high tumor
burden in the first place making extended hepatectomy necessary. Repeat hepatectomy for recurrence
could not be offered and these patients died within the first year after recurrence. In contrast,
patients who died of intrahepatic recurrence following minor MIH in Bern could undergo repeat
parenchymal-sparing liver resection for single CRLM and lived for another two years. The fact that
more patients in Berlin than in Bern died without recurrence from non-cancer related causes, could be
one reason for the higher DFS but lower OS in Berlin (not statistically significant differences).
In the current literature, the optimal extent of hepatic resection remains unclear. Often,
no differences were found between parenchymal-sparing and anatomic resections [55,56], but the
current trend moves towards parenchymal-sparing resections [57]. In this regard, CRLM needs to be
acknowledged as a chronic disease. By limiting hepatectomies to parenchymal-sparing resections
whenever possible, re-resections for recurrent CRLM are made possible [58]. Interestingly, improved
oncologic outcomes were not associated with an increase in margin width for R0 resections [59] leading
to the recommendation in the current Southampton guidelines that parenchymal-sparing resections
should be preferably conducted for patients with CRLM [15], which was implemented in both centers if
this was allowed by the extent of the tumor burden. Nevertheless, prolonged OS could be achieved in
both centers in our study, and especially DFS was not compromised by parenchymal-sparing resections.
In summary, despite of favorable short-term and comparable long-term outcomes after MIH found in
this study, the decision for either MIH or OH should be individually made for each patient and should
be based on patient- and tumor-related factors.
Our present retrospective study has also several limitations. Firstly, conclusions should be
carefully drawn due to the rather small cohorts and the retrospective nature of data collection.
We tried to challenge this issue by establishing a bi-centric cohort pooling data from two specialized
centers with large experience in hepatobiliary surgery. Surgeon- and center-related bias have been
eliminated by matching MIH with OH for each center separately. Thus, we could assure that
same number of OH and MIH were included from each center, respectively. In addition, it was
our objective to create a meaningful statistical comparison by performing PSM to eliminate known
covariates. Nevertheless, unused and especially unknown confounders could have influenced our
results. Of note, the investigation of somatic gene mutations gains increasingly importance in the
treatment of CRLM [60–62]; however, this was not within the scope of this study. The introduction of
laparoscopic surgery for CRLM during the study period is associated with a possible learning curve,
which may have influenced the outcomes [63,64]. However, standardized laparoscopic procedures
performed by experienced hepatobiliary surgeons in both high-volume centers resulted in favorable
short- and long-term outcomes underling the advantages of MIH for CRLM.
5. Conclusions
MIH for CRLM was associated with lower overall postoperative morbidity, and shorter length
of ICU and hospital stay compared to OH. Oncologic outcomes after MIH were at least equivalent
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compared to those after OH. Therefore, our results support our current approach that MIH should be
preferred for patients presenting with resectable CRLM.
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